CEACAM5 and pachyonychia congenita: The clinical utility targets high-risk patients such as patients with new-onset diabetes (> 50 years), chronic pancreatitis, unexplained weight loss + abdominal pain and incidental elevated biomarker (CA 19-9, CEA, ALP) which are likely developing of PC.